Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: A systematic review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 10, 2012, Pages 5177-5182

  Qi, Wei Xiang ^a   Shen, Zan ^a   Lin, Feng ^a   Sun, Yuan Jue ^a   Min, Da Liu ^a   Tang, Li Na ^a   He, Ai Na ^a   Yao, Yang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Docetaxel; Erlotinib; Gefitinib; Meta analysis; Non small cell lung cancer; Pemetrexed; Second line

Indexed keywords

EID: 84874003623     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.10.5177     Document Type: Article

References (31)

1. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
2. Cufer T, Vrdoljak E, Gaafar R, et al (2006). Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs, 17, 401-9.
3. Ciuleanu T, Stelmakh L, Cicenas S, et al (2012). Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 13, 300-8.
4. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
5. Fossella FV, DeVore R, Kerr RN, et al (2000). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, 18, 2354-62.
6. Garassino MC, Martelli O, Bettini A, et al (2012). TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol, 30, abstr LBA7501.
7. Jiang H (2009). Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol, 39, 137-50.
8. Jiang J, Huang L, Liang X, et al (2011). Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Acta Oncol, 50, 582-8.
9. Kim ES, Hirsh V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 372, 1809-18.
10. Kim ST, Uhm JE, Lee J, et al(2012). Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer, 75, 82-8.
11. Lee DH, Park K, Kim JH, et al (2010). Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res, 16, 1307-14.
12. Li H, Zhuang Y, Xiu Y, et al (2010). Second-line treatment with gefitinib or docetaxel for advanced non-small cell lung cancer. Chin J Clin Oncol, 37, 16-8 (article in chinese).
13. Maruyama R, Nishiwaki Y, Tamura T et al (2008). Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol, 26, 4244-52.
14. Moher D, Pham B, Jones A, et al (1998). Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet, 352, 609-13.
15. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
16. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
17. Passaro A, Cortesi E, de Marinis F (2011). Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. Expert Rev Anticancer Ther, 11, 1587-97.
18. Qi WX, Shen Z, Yao Y (2012). Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 69, 99-106.
19. Qi WX, Tang LN, He AN, et al (2012). Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 138, 745-51.
20. Rossi A, Ricciardi S, Maione P, et al (2009). Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer, 66, 141-9.
21. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.
22. Shepherd FA, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32.
24. Stinchcombe TE, Socinski MA (2009). Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol, 4, 243-50.
25. Sun JM, Lee KH, Kim SW, et al (2012). Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): An open-label, phase 3 trial. Cancer 2012.
26. Thatcher N, Chang A, Parikh P, et al(2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-37.
27. Uhm JE, Park BB, Ahn MJ, et al (2009). Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. J Thorac Oncol, 4, 1136-43.
28. Vamvakas L, Agelaki S, Kentepozidis NK, et al (2010). Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol, 28, abstr 7519.
29. Vandenbroucke JP (1998). Bias in meta-analysis detected by a simple, graphical test. Experts' views are still needed. BMJ, 316, 469-70.
30. Yang CH (2008). EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer, 60, S23-30.
31. Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol, 28, 123-37.